3 not yet recruiting, 2 completed, 1 recruiting, 1 unknown. 4 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Not yet recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow Jina Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer 50 mg cabazitaxel, 100 mg cabazitaxel, 200 mg cabazitaxel - Metastatic Castration-resistant Prostate Cancer, MCRPC | Phase 2 | Not yet recruiting | Jina Pharmaceuticals Inc. | 75 | 2025-05-01 | 2025-03-24 |
| Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer Paclitaxel Lipid Suspension, Conventional paclitaxel or Taxol - Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | Phase 3 | Not yet recruiting | Jina Pharmaceuticals Inc. | 166 | 2025-04-01 | 2025-03-10 |
| Tacrolimus Lipid Suspension for Enema in Adult Subjects with Mild to Moderately Active Left-sided/Distal Ulcerative Colitis Who Had an Inadequate Response to the Treatment Tacrolimus Lipid Suspension for enema, Identical Tacrolimus-free Lipid Suspension for Enema - Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | Phase 2 | Not yet recruiting | Jina Pharmaceuticals Inc. | 150 | 2025-04-01 | 2025-03-12 |
| Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients Endoxifen enteric-coated tablet (8 mg), Placebo Tablets - Bipolar 1 Disorder | Phase 3 | Unknown | Jina Pharmaceuticals Inc. | 490 | 2024-03-19 | 2025-03-17 |
| Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients Endoxifen, Placebo oral tablet - Bipolar I Disorder | Phase 3 | Completed | Jina Pharmaceuticals Inc. | 124 | 2020-08-03 | 2024-09-23 |
| A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2), Taxotere® (100 mg/m2) - Triple Negative Breast Cancer | Phase 3 | Recruiting | Jina Pharmaceuticals Inc. | 657 | 2018-07-10 | 2025-03-21 |
| Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors nanosomal docetaxel lipid suspension, pharmacological study - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of Southern California | 13 | 2013-11-08 | 2017-04-11 |
Colitis, Ulcerative (1) · Triple Negative Breast Neoplasms (1)
4-hydroxy-N-desmethyltamoxifen (1) · Docetaxel (1) · Enema (1) · Paclitaxel (1) · cabazitaxel (1)
United States (4) · India (1)
Anthony El-Khoueiry (1) · Dr. Ravi Alamchandani (1) · Theodore R Treese, MD (1)
P30CA014089 (1)